Evidence map›Paper›PMID 38687439›Full record

ArticleFamilial cancer2024

A comprehensive characterization of the spectrum of MUTYH germline pathogenic variants in Latin America.

Patricia Esperon, Florencia Neffa, Walter Pavicic, Florencia Spirandelli, Karin Alvarez, María José Mullins, Benedito Mauro Rossi, Rodrigo Felipe Góngora E Silva, Carlos Vaccaro, Francisco Lopéz-Köstner and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Familial cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Patricia EsperonHospital Fuerzas Armadas, Grupo Colaborativo Uruguayo, Investigación de Afecciones Oncológicas Hereditarias (GCU), Montevideo, Uruguay. pesperon@fq.edu.uy.
Florencia NeffaHospital Fuerzas Armadas, Grupo Colaborativo Uruguayo, Investigación de Afecciones Oncológicas Hereditarias (GCU), Montevideo, Uruguay.
Walter PavicicPrograma de Cáncer Hereditario (Pro.Can.He.), Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
Florencia SpirandelliSanatorio Parque GO, Rosario, Argentina.
Karin AlvarezClínica Universidad de los Andes, Chile, Programa Cáncer Heredo Familiar, Santiago, Chile.
María José MullinsDepartamento de Oncología, Centro de la Mama, Programa de Asesoría Genética en Oncología, Clínica Alemana, Santiago, Chile.
Benedito Mauro RossiHospital Beneficência Portuguesa, São Paulo, Brazil.
Rodrigo Felipe Góngora E SilvaHospital Sírio-Libanês, São Paulo, Brazil.
Carlos VaccaroInstituto de Medicina Traslacional e Ingenieria Biomedica (IMTIB, CONICET), Buenos Aires, Argentina.
Francisco Lopéz-KöstnerClínica Universidad de los Andes, Chile, Programa Cáncer Heredo Familiar, Santiago, Chile.
Jorge RugelesClínica IMAT Oncomedica Auna, Monteria, Colombia.
Adriana Della ValleHospital Fuerzas Armadas, Grupo Colaborativo Uruguayo, Investigación de Afecciones Oncológicas Hereditarias (GCU), Montevideo, Uruguay.
Mev Dominguez-ValentinDepartment of Tumor Biology, Institute of Cancer Research, The Norwegian Radium Hospital, 0379, Oslo, Norway.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MUTYH-Associated Polyposis (MAP) is caused by biallelic pathogenic germline variants in the MUTYH gene. However, individuals harboring monoallelic MUTYH pathogenic variants in the presence of a positive family history have been reported to have a twofold increased risk of colorectal cancer (CRC) and extra colonic cancers. Our aim was to characterize the spectrum of monoallelic and biallelic germline MUTYH pathogenic variants in Latin American patients and to describe their clinical and genetic characteristics. Patients were identified from eight high-risk genetic cancer centers of five Latin American countries. Statistical analysis was performed using the two-sided P test using the Vassarstats statistical tools. Statistical significance was set at a p value ≤ 0.05. Of the 105 unrelated patients with cancer or colorectal polyposis, 84.8% and 15.2% carried pathogenic monoallelic and biallelic MUTYH variants, respectively. The most common pathogenic variants were p.Gly396Asp and p.Tyr179Cys (55% and 23%, respectively). The mean age at first diagnosis was 48.29 years (range 31-71) and 49.90 years (range 27-87) in biallelic and monoallelic MUTYH patients, respectively. CRC was the only cancer diagnosed in patients with biallelic MUTYH pathogenic variants (75%), while breast cancer (46.1%) was more common than CRC (24.7%) in individuals with monoallelic MUTYH pathogenic variants. We reported a high frequency of European founder variants in our diverse population. Some phenotypic differences from current studies were identified, such as a higher breast cancer burden in monoallelic carriers and a complete absence of extra-colon tumors in biallelic patients.

Indexed as

DNA GlycosylasesGenetic Predisposition to DiseaseGerm-Line MutationAdenomatous Polyposis ColiAdultAgedAged, 80 and overColorectal NeoplasmsFemaleHumansLatin AmericaMaleMiddle AgedDNA GlycosylasesmutY adenine glycosylaseGenotypeLatin AmericaMUTYHPhenotype

Identifiers

PMID38687439

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.